Host Control of Fungal Infections: Lessons from Basic Studies and Human Cohorts

Annual Review of Immunology

Volumn 36, Issue , 2018, Pages 157-191

  Lionakis, Michail S ^a   Levitz, Stuart M ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Acquired immunodeficiencies; Antifungal immunity; Fungal vaccines; Fungi; Immunotherapy; Monogenic disorders

Indexed keywords

ANTIBODY; BIOLOGICAL PRODUCT; CYTOKINE; FUNGUS VACCINE; PATTERN RECOGNITION RECEPTOR; PHOSPHOTRANSFERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; CELL SURFACE; CELLULAR IMMUNITY; CLINICAL PATHWAY; COHORT ANALYSIS; DENDRITIC CELL; DERMATOMYCOSIS; DRUG TARGETING; EFFECTOR CELL; FUNGUS IMMUNITY; HOST; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; INFECTION CONTROL; INFECTION PREVENTION; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LEUKOCYTE FUNCTION; LYMPHOCYTE FUNCTION; MACROPHAGE; MONOCYTE; MYCOSIS; NEUTROPHIL; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGEN CLEARANCE; PHAGOCYTE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC DISEASE; T LYMPHOCYTE; TRANSPLANTATION; ANIMAL; COMPLICATION; CYTOLOGY; DISEASE PREDISPOSITION; FUNGUS; IMMUNE SYSTEM; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; METABOLISM; MICROBIOLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ANIMALS; DISEASE SUSCEPTIBILITY; FUNGAL VACCINES; FUNGI; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY; MYCOSES; SIGNAL TRANSDUCTION;

EID: 85045933755     PISSN: 07320582     EISSN: 15453278     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-042617-053318     Document Type: Review

References (200)

1. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG,White TC. 2012. Hidden killers: human fungal infections. Sci. Transl. Med. 4:165rv13
2. Fisher MC, Henk DA, Briggs CJ, Brownstein JS, Madoff LC, et al. 2012. Emerging fungal threats to animal, plant and ecosystem health. Nature 484:186-94
3. Wu F, Groopman JD, Pestka JJ. 2014. Public health impacts of foodborne mycotoxins. Annu. Rev. Food Sci. Technol. 5:351-72
4. Kauffman HF. 2006. Innate immune responses to environmental allergens. Clin. Rev. Allergy Immunol. 30:129-40
5. Iliev ID, Leonardi I. 2017. Fungal dysbiosis: immunity and interactions at mucosal barriers. Nat. Rev. Immunol. 17:635-46
6. Erwig LP, GowNA. 2016. Interactions of fungal pathogens with phagocytes. Nat. Rev.Microbiol. 14:163-76
7. Brown GD. 2011. Innate antifungal immunity: the key role of phagocytes. Annu. Rev. Immunol. 29:1-21
8. NeteaMG, Brown GD, Kullberg BJ, GowNA. 2008. An integrated model of the recognition of Candida albicans by the innate immune system. Nat. Rev. Microbiol. 6:67-78
9. Gringhuis SI, Kaptein TM, Wevers BA, Theelen B, van der Vlist M, et al. 2012. Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1β via a noncanonical caspase-8 inflammasome. Nat. Immunol. 13:246-54
10. GrossO, Poeck H, BscheiderM,Dostert C, Hannesschlager N, et al. 2009. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature 459:433-6
11. Karki R, Man SM, Malireddi RK, Gurung P, Vogel P, et al. 2015. Concerted activation of the AIM2 and NLRP3 inflammasomes orchestrates host protection against Aspergillus infection. Cell Host Microbe 17:357-68
12. Tomalka J, Ganesan S, Azodi E, Patel K, Majmudar P, et al. 2011. A novel role for the NLRC4 inflammasome in mucosal defenses against the fungal pathogen Candida albicans. PLOS Pathog. 7:e1002379
13. Ishikawa T, Itoh F, Yoshida S, Saijo S, Matsuzawa T, et al. 2013. Identification of distinct ligands for the C-type lectin receptors Mincle and Dectin-2 in the pathogenic fungus Malassezia. Cell Host Microbe 13:477-88
14. Marakalala MJ, Vautier S, Potrykus J, Walker LA, Shepardson KM, et al. 2013. Differential adaptation of Candida albicans in vivo modulates immune recognition by Dectin-1. PLOS Pathog. 9:e1003315
15. SousaMGT, BeldaWJr., Spina R, Lota PR, Valente NS, et al. 2014. Topical application of imiquimod as a treatment for chromoblastomycosis. Clin. Infect. Dis. 58:1734-37
16. Sousa MGT, Reid DM, Schweighoffer E, Tybulewicz V, Ruland J, et al. 2011. Restoration of pattern recognition receptor costimulation to treat chromoblastomycosis, a chronic fungal infection of the skin. Cell Host Microbe 9:436-43
17. Deng Z, Ma S, Zhou H, Zang A, Fang Y, et al. 2015. Tyrosine phosphatase SHP-2 mediates C-type lectin receptor-induced activation of the kinase Syk and anti-fungal TH17 responses. Nat. Immunol. 16:642-52
18. Cao Z, Conway KL, Heath RJ, Rush JS, Leshchiner ES, et al. 2015. Ubiquitin ligase TRIM62 regulates CARD9-mediated anti-fungal immunity and intestinal inflammation. Immunity 43:715-26
19. Roth S, Bergmann H, Jaeger M, Yeroslaviz A, Neumann K, et al. 2016. Vav proteins are key regulators of Card9 signaling for innate antifungal immunity. Cell Rep. 17:2572-83
20. Strasser D, Neumann K, Bergmann H, Marakalala MJ, Guler R, et al. 2012. Syk kinase-coupled Ctype lectin receptors engage protein kinase C-sigma to elicit Card9 adaptor-mediated innate immunity. Immunity 36:32-42
21. Jia XM, Tang B, Zhu LL, Liu YH, Zhao XQ, et al. 2014. CARD9 mediates Dectin-1-induced ERK activation by linking Ras-GRF1 to H-Ras for antifungal immunity. J. Exp. Med. 211:2307-21
22. Gorjestani S, Yu M, Tang B, Zhang D, Wang D, Lin X. 2011. Phospholipase Cγ2 (PLCγ2) is key component in Dectin-2 signaling pathway, mediating anti-fungal innate immune responses. J. Biol. Chem. 286:43651-59
23. Gringhuis SI, den Dunnen J, Litjens M, van der Vlist M, Wevers B, et al. 2009. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kB activation through Raf-1 and Syk. Nat. Immunol. 10:203-13
24. GrossO,Gewies A, FingerK, Schafer M, SparwasserT, et al. 2006. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature 442:651-56
25. Whitney PG, Bar E, Osorio F, Rogers NC, Schraml BU, et al. 2014. Syk signaling in dendritic cells orchestrates innate resistance to systemic fungal infection. PLOS Pathog. 10:e1004276
26. Zhao X, Guo Y, Jiang C, Chang Q, Zhang S, et al. 2017. JNK1 negatively controls antifungal innate immunity by suppressing CD23 expression. Nat. Med. 23:337-46
27. Xiao Y, Tang J, GuoH, Zhao Y,Tang R, et al. 2016. TargetingCBLB as a potential therapeutic approach for disseminated candidiasis. Nat. Med. 22:906-14
28. Romani L, Mencacci A, Cenci E, Del Sero G, Bistoni F, Puccetti P. 1997. An immunoregulatory role for neutrophils in CD4+ T helper subset selection in mice with candidiasis. J. Immunol. 158:2356-62
29. Lionakis MS, Lim JK, Lee CC, Murphy PM. 2011. Organ-specific innate immune responses in a mouse model of invasive candidiasis. J. Innate Immun. 3:180-99
30. Jhingran A, Kasahara S, Shepardson KM, Junecko BA, Heung LJ, et al. 2015. Compartment-specific and sequential role of MyD88 and CARD9 in chemokine induction and innate defense during respiratory fungal infection. PLOS Pathog. 11:e1004589
31. Mehrad B, Strieter RM,MooreTA, TsaiWC, Lira SA, Standiford TJ. 1999.CXCchemokine receptor-2 ligands are necessary components of neutrophil-mediated host defense in invasive pulmonary aspergillosis. J. Immunol. 163:6086-94
32. Caffrey AK, Lehmann MM, Zickovich JM, Espinosa V, Shepardson KM, et al. 2015. IL-1α signaling is critical for leukocyte recruitment after pulmonary Aspergillus fumigatus challenge. PLOS Pathog. 11:e1004625
33. Gazendam RP, van Hamme JL, Tool AT, Hoogenboezem M, van den Berg JM, et al. 2016. Human neutrophils use different mechanisms to kill Aspergillus fumigatus conidia and hyphae: evidence from phagocyte defects. J. Immunol. 196:1272-83
34. Gazendam RP, van Hamme JL, Tool AT, van Houdt M, Verkuijlen PJ, et al. 2014. Two independent killing mechanisms of Candida albicans by human neutrophils: evidence from innate immunity defects. Blood 124:590-97
35. Zarember KA, Sugui JA, Chang YC, Kwon-Chung KJ, Gallin JI. 2007. Human polymorphonuclear leukocytes inhibit Aspergillus fumigatus conidial growth by lactoferrin-mediated iron depletion. J. Immunol. 178:6367-73
36. Branzk N, Lubojemska A,Hardison SE, Wang Q, GutierrezMG, et al. 2014. Neutrophils sensemicrobe size and selectively release neutrophil extracellular traps in response to large pathogens. Nat. Immunol. 15:1017-25
37. Clark HL, Jhingran A, Sun Y, Vareechon C, de Jesus Carrion S, et al. 2016. Zinc and manganese chelation by neutrophil S100A8/A9 (calprotectin) limits extracellular Aspergillus fumigatus hyphal growth and corneal infection. J. Immunol. 196:336-44
38. Urban CF, Reichard U, Brinkmann V, Zychlinsky A. 2006. Neutrophil extracellular traps capture and kill Candida albicans yeast and hyphal forms. Cell. Microbiol. 8:668-76
39. Garg AV, Amatya N, Chen K, Cruz JA, Grover P, et al. 2015. MCPIP1 endoribonuclease activity negatively regulates interleukin-17-mediated signaling and inflammation. Immunity 43:475-87
40. Lionakis MS, Fischer BG, Lim JK, Swamydas M, Wan W, et al. 2012. Chemokine receptor Ccr1 drives neutrophil-mediated kidney immunopathology and mortality in invasive candidiasis. PLOS Pathog. 8:e1002865
41. Zwolanek F, Riedelberger M, Stolz V, Jenull S, Istel F, et al. 2014. The non-receptor tyrosine kinase Tec controls assembly and activity of the noncanonical caspase-8 inflammasome. PLOS Pathog. 10:e1004525
42. Espinosa V, Jhingran A, Dutta O, Kasahara S, Donnelly R, et al. 2014. Inflammatory monocytes orchestrate innate antifungal immunity in the lung. PLOS Pathog. 10:e1003940
43. Ngo LY, Kasahara S, Kumasaka DK, Knoblaugh SE, Jhingran A,Hohl TM. 2014. Inflammatory monocytes mediate early and organ-specific innate defense during systemic candidiasis. J. Infect. Dis. 209:109-19
44. Szymczak WA, Deepe GS Jr. 2009. The CCL7-CCL2-CCR2 axis regulates IL-4 production in lungs and fungal immunity. J. Immunol. 183:1964-74
45. Phadke AP, Akangire G, Park SJ, Lira SA, Mehrad B. 2007. The role of CC chemokine receptor 6 in host defense in a model of invasive pulmonary aspergillosis. Am. J. Respir. Crit. Care Med. 175:1165-72
46. Sterkel AK, Lorenzini JL, Fites JS, Subramanian Vignesh K, Sullivan TD, et al. 2016. Fungal mimicry of a mammalian aminopeptidase disables innate immunity and promotes pathogenicity. Cell HostMicrobe 19:361-74
47. Lionakis MS, Swamydas M, Fischer BG, Plantinga TS, Johnson MD, et al. 2013. CX3CR1-dependent renal macrophage survival promotes Candida control and host survival. J. Clin. Invest. 123:5035-51
48. Subramanian Vignesh K, Landero Figueroa JA, Porollo A, Caruso JA, Deepe GS Jr. 2013. Granulocyte macrophage-colony stimulating factor induced Zn sequestration enhances macrophage superoxide and limits intracellular pathogen survival. Immunity 39:697-710
49. AkoumianakiT,Kyrmizi I, Valsecchi I,GresnigtMS, SamonisG, et al. 2016. Aspergillus cell wall melanin blocks LC3-associated phagocytosis to promote pathogenicity. Cell Host Microbe 19:79-90
50. Cheng SC, Quintin J, Cramer RA, Shepardson KM, Saeed S, et al. 2014. mTOR-and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 345:1250684
51. Ramirez-Ortiz ZG, Lee CK, Wang JP, Boon L, Specht CA, Levitz SM. 2011. A nonredundant role for plasmacytoid dendritic cells in host defense against the human fungal pathogen Aspergillus fumigatus. Cell Host Microbe 9:415-24
52. Araujo EF, Medeiros DH, Galdino NA, Condino-Neto A, Calich VL, Loures FV. 2016. Tolerogenic plasmacytoid dendritic cells control Paracoccidioides brasiliensis infection by inducting regulatory T cells in an IDO-dependent manner. PLOS Pathog. 12:e1006115
53. Guerra ES, Lee CK, Specht CA, Yadav B, Huang H, et al. 2017. Central role of IL-23 and IL-17 producing eosinophils as immunomodulatory effector cells in acute pulmonary aspergillosis and allergic asthma. PLOS Pathog. 13:e1006175
54. Bar E, Whitney PG, Moor K, Sousa CR, LeibundGut-Landmann S. 2014. IL-17 regulates systemic fungal immunity by controlling the functional competence of NK cells. Immunity 40:117-27
55. Dominguez-Andres J, Feo-Lucas L, Minguito de la Escalera M, Gonzalez L, Lopez-Bravo M, Ardavin C. 2017. Inflammatory Ly6Chigh monocytes protect against candidiasis through IL-15-driven NK cell/neutrophil activation. Immunity 46:1059-72.e4
56. Li SS, Kyei SK, Timm-McCann M, Ogbomo H, Jones GJ, et al. 2013. The NK receptor NKp30 mediates direct fungal recognition and killing and is diminished in NK cells from HIV-infected patients. Cell Host Microbe 14:387-97
57. Park SJ,HughesMA, Burdick M, Strieter RM,Mehrad B. 2009. EarlyNKcell-derived IFN-γ is essential to host defense in neutropenic invasive aspergillosis. J. Immunol. 182:4306-12
58. Cohen NR, Tatituri RV, Rivera A, Watts GF, Kim EY, et al. 2011. Innate recognition of cell wall β-glucans drives invariant natural killer T cell responses against fungi. Cell Host Microbe 10:437-50
59. Steele C, Zheng M, Young E, Marrero L, Shellito JE, Kolls JK. 2002. Increased host resistance against Pneumocystis carinii pneumonia in γδ T-cell-deficient mice: protective role of gamma interferon and CD8+ T cells. Infect. Immun. 70:5208-15
60. Conti HR, Peterson AC, Brane L, Huppler AR, Hernandez-Santos N, et al. 2014. Oral-resident natural Th17 cells and γδT cells control opportunistic Candida albicans infections. J. Exp. Med. 211:2075-84
61. Kashem SW, RiedlMS, YaoC,Honda CN,Vulchanova L, Kaplan DH. 2015. Nociceptive sensory fibers drive interleukin-23 production from CD301b+ dermal dendritic cells and drive protective cutaneous immunity. Immunity 43:515-26
62. St. Leger AJ, Desai JV, Drummond RA, Kugadas A, Almaghrabi F, et al. 2017. An ocular commensal protects against corneal infection by driving an interleukin-17 response from mucosal γδ T cells. Immunity 47:148-58.e5
63. Liu H, Lee MJ, Solis NV, Phan QT, Swidergall M, et al. 2016. Aspergillus fumigatus CalA binds to integrin α5β1 and mediates host cell invasion. Nat. Microbiol. 2:16211
64. Phan QT, Myers CL, Fu Y, Sheppard DC, Yeaman MR, et al. 2007. Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLOS Biol. 5:e64
65. Moyes DL, Wilson D, Richardson JP,Mogavero S,Tang SX, et al. 2016. Candidalysin is a fungal peptide toxin critical for mucosal infection. Nature 532:64-68
66. Altmeier S, Toska A, Sparber F, Teijeira A, Halin C, LeibundGut-Landmann S. 2016. IL-1 coordinates the neutrophil response to C. albicans in the oral mucosa. PLOS Pathog. 12:e1005882
67. Gebremariam T, Lin L, Liu M, Kontoyiannis DP, French S, et al. 2016. Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. J. Clin. Investig. 126:2280-94
68. Wuthrich M, Deepe GS Jr., Klein B. 2012. Adaptive immunity to fungi. Annu. Rev. Immunol. 30:115-48
69. Huang H, Ostroff GR, Lee CK, Agarwal S, Ram S, et al. 2012. Relative contributions of Dectin-1 and complement to immune responses to particulate β-glucans. J. Immunol. 189:312-17
70. Zielinski CE, Mele F, Aschenbrenner D, Jarrossay D, Ronchi F, et al. 2012. Pathogen-induced human TH17 cells produce IFN-γor IL-10 and are regulated by IL-1β. Nature 484:514-18
71. Eddens T, ElsegeinyW,Luz Garcia-HernadezM,Castillo P, Trevejo-NunezG, et al. 2017. Pneumocystisdriven inducible bronchus-associated lymphoid tissue formation requires Th2 and Th17 immunity. Cell Rep. 18:3078-90
72. Zelante T, Iannitti R, De Luca A, Romani L. 2011. IL-22 in antifungal immunity. Eur. J. Immunol. 41:270-75
73. Araujo EF, Medeiros DH, Galdino NA, Condino-Neto A, Calich VL, Loures FV. 2016. Tolerogenic plasmacytoid dendritic cells control Paracoccidioides brasiliensis infection by inducting regulatory T cells in an IDO-dependent manner. PLOS Pathog. 12:e1006115
74. Ochs HD, Gambineri E, Torgerson TR. 2007. IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. Immunol. Res. 38:112-21
75. Bystrom J, Taher TE, Muhyaddin MS, Clanchy FI, Mangat P, et al. 2015. Harnessing the therapeutic potential of Th17 cells. Mediat. Inflamm. 2015:205156
76. De Luca A, Zelante T, D'Angelo C, Zagarella S, Fallarino F, et al. 2010. IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol. 3:361-73
77. Walkovich K, Vander Lugt M. 2017. ZAP70-related combined immunodeficiency. GeneReviews, updated June 8. Univ.Wash., Seattle, Wash.
78. Nanjappa SG, McDermott AJ, Fites JS, Galles K, Wuthrich M, et al. 2017. Antifungal Tc17 cells are durable and stable, persisting as long-lasting vaccine memory without plasticity towards IFNγ cells. PLOS Pathog. 13:e1006356
79. Casadevall A, Pirofski LA. 2012. Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases. Cell Host Microbe 11:447-56
80. Nabavi N, Murphy JW. 1986. Antibody-dependent natural killer cell-mediated growth inhibition of Cryptococcus neoformans. Infect. Immun. 51:556-62
81. Torosantucci A, Bromuro C, Chiani P, De Bernardis F, Berti F, et al. 2005. A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. 202:597-606
82. McClelland EE, Nicola AM, Prados-Rosales R, Casadevall A. 2010. Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism. J. Clin. Investig. 120:1355-61
83. BowenA,WearMP, CorderoRJB, Oscarson S, Casadevall A. 2017.Amonoclonal antibody to Cryptococcus neoformans glucuronoxylomannan manifests hydrolytic activity for both peptides and polysaccharides. J. Biol. Chem. 292:417-34
84. van Spriel AB, SofiM,Gartlan KH, van der Schaaf A, Verschueren I, et al. 2009. The tetraspanin protein CD37 regulates IgA responses and anti-fungal immunity. PLOS Pathog. 5:e1000338
85. Rapaka RR, Ricks DM, Alcorn JF, Chen K, Khader SA, et al. 2010. Conserved natural IgM antibodies mediate innate and adaptive immunity against the opportunistic fungus Pneumocystis murina. J. Exp. Med. 207:2907-19
86. Ahn IE, Jerussi T, Farooqui M, Tian X, Wiestner A, Gea-Banacloche J. 2016. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood 128:1940-43
87. Boisson B, Wang C, Pedergnana V, Wu L, Cypowyj S, et al. 2013. An ACT1 mutation selectively abolishes interleukin-17 responses in humanswith chronic mucocutaneous candidiasis. Immunity 39:676-86
88. Levy R, Okada S, Beziat V, Moriya K, Liu C, et al. 2016. Genetic, immunological, and clinical features of patients with bacterial and fungal infections due to inherited IL-17RA deficiency. PNAS 113:E8277-85
89. Ling Y, Cypowyj S, Aytekin C, Galicchio M, Camcioglu Y, et al. 2015. Inherited IL-17RC deficiency in patients with chronic mucocutaneous candidiasis. J. Exp. Med. 212:619-31
90. Lionakis MS, Netea MG, Holland SM. 2014. Mendelian genetics of human susceptibility to fungal infection. Cold Spring Harb. Perspect. Med. 4:a019638
91. Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, et al. 2008. Impaired TH17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452:773-76
92. Okada S,Markle JG, Deenick EK,Mele F, Averbuch D, et al. 2015. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations. Science 349:606-13
93. Toubiana J, Okada S, Hiller J, Oleastro M, Lagos Gomez M, et al. for Int. STAT1 Gain Funct. Stud. Group. 2016. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood 127:3154-64
94. van deVeerdonk FL, PlantingaTS, Hoischen A, Smeekens SP, Joosten LA, et al. 2011. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N. Engl. J. Med. 365:54-61
95. Zhang Y, Ma CA, Lawrence MG, Break TJ, O'Connell MP, et al. 2017. PD-L1 up-regulation restrains Th17 cell differentiation in STAT3 loss-and STAT1 gain-of-function patients. J. Exp. Med. 214:2523
96. WeinachtKG, Charbonnier LM,Alroqi F, Plant A,Qiao Q, et al. 2017. Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. J. Allergy Clin. Immunol. 139:1629-40.e2
97. Ferre EM,Rose SR, Rosenzweig SD, Burbelo PD,RomitoKR, et al. 2016. Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight 1:e88782
98. Puel A, Doffinger R, Natividad A, ChrabiehM, Barcenas-Morales G, et al. 2010. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronicmucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J. Exp. Med. 207:291-97
99. Shlezinger N, Irmer H, Dhingra S, Beattie SR, Cramer RA, et al. 2017. Sterilizing immunity in the lung relies on targeting fungal apoptosis-like programmed cell death. Science. 357:1037-41
100. Kuhns DB, AlvordWG, Heller T, Feld JJ, Pike KM, et al. 2010. Residual NADPH oxidase and survival in chronic granulomatous disease. N. Engl. J. Med. 363:2600-10
101. Bianchi M, Hakkim A, Brinkmann V, Siler U, Seger RA, et al. 2009. Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood 114:2619-22
102. Int. Chronic Granulomatous Dis. Coop. Study Group. 1991. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N. Engl. J. Med. 324:509-16
103. Dalgic B, Bukulmez A, Sari S. 2011. Pyogenic liver abscess and peritonitis due to Rhizopus oryzae in a child with Papillon-Lefevre syndrome. Eur. J. Pediatr. 170:803-5
104. Swamydas M, Gao JL, Break TJ, Johnson MD, Jaeger M, et al. 2016. CXCR1-mediated neutrophil degranulation and fungal killing promote Candida clearance and host survival. Sci. Transl.Med. 8:322ra10
105. WirnsbergerG, Zwolanek F, Stadlmann J,Tortola L, Liu SW, et al. 2014. Jagunal homolog 1 is a critical regulator of neutrophil function in fungal host defense. Nat. Genet. 46:1028-33
106. Plantinga TS, Johnson MD, Scott WK, van de Vosse E, Velez Edwards DR, et al. 2012. Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. J. Infect. Dis. 205:934-43
107. Picard C, Casanova JL, Puel A. 2011. Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IkBαdeficiency. Clin. Microbiol. Rev. 24:490-97
108. Rosenfeld SI, Kelly ME, Leddy JP. 1976. Hereditary deficiency of the fifth component of complement in man: I. Clinical, immunochemical, and family studies. J. Clin. Investig. 57:1626-34
109. Glocker EO, Hennigs A, Nabavi M, Schaffer AA, Woellner C, et al. 2009. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N. Engl. J. Med. 361:1727-35
110. Rieber N, Gazendam RP, Freeman AF, Hsu AP, Collar AL, et al. 2016. Extrapulmonary Aspergillus infection in patients with CARD9 deficiency. JCI Insight 1:e89890
111. Lanternier F, Barbati E, Meinzer U, Liu L, Pedergnana V, et al. 2015. Inherited CARD9 deficiency in 2 unrelated patients with invasive Exophiala infection. J. Infect. Dis. 211:1241-50
112. Lanternier F, Pathan S, Vincent QB, Liu L, Cypowyj S, et al. 2013. Deep dermatophytosis and inherited CARD9 deficiency. N. Engl. J. Med. 369:1704-14
113. Drummond RA, Collar AL, Swamydas M, Rodriguez CA, Lim JK, et al. 2015. CARD9-dependent neutrophil recruitment protects against fungal invasion of the central nervous system. PLOS Pathog. 11:e1005293
114. Drewniak A, Gazendam RP, Tool AT, van Houdt M, Jansen MH, et al. 2013. Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency. Blood 121:2385-92
115. Gavino C, Hamel N, Zeng JB, Legault C, Guiot MC, et al. 2016. Impaired RASGRF1/ERK-mediated GM-CSF response characterizes CARD9 deficiency in French-Canadians. J. Allergy Clin. Immunol. 137:1178-88.e7
116. Browne SK, Burbelo PD, Chetchotisakd P, Suputtamongkol Y, Kiertiburanakul S, et al. 2012. Adultonset immunodeficiency in Thailand and Taiwan. N. Engl. J. Med. 367:725-34
117. Saijo T, Chen J, Chen SC, Rosen LB, Yi J, et al. 2014. Anti-granulocyte-macrophage colony-stimulating factor autoantibodies are a risk factor for central nervous system infection by Cryptococcus gattii in otherwise immunocompetent patients. mBio 5:e00912-14
118. Seitz AE, Prevots DR,Holland SM. 2012. Hospitalizations associated with disseminated coccidioidomycosis, Arizona and California, USA. Emerg. Infect. Dis. 18:1476-79
119. Loose DS, Stover EP, Restrepo A, Stevens DA, Feldman D. 1983. Estradiol binds to a receptor-like cytosol binding protein and initiates a biological response in Paracoccidioides brasiliensis. PNAS 80:7659-63
120. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, et al. 2017. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect. Dis. 17:873-81
121. Goupil M, Cousineau-Cote V, Aumont F, Senechal S, Gaboury L, et al. 2014. Defective IL-17-and IL-22-dependent mucosal host response to Candida albicans determines susceptibility to oral candidiasis in mice expressing the HIV-1 transgene. BMC Immunol. 15:49
122. Pirotta MV,Garland SM. 2006. Genital Candida species detected in samples from women inMelbourne, Australia, before and after treatment with antibiotics. J. Clin. Microbiol. 44:3213-17
123. Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G, et al. 2013. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 39:372-85
124. Jarvis JN, Casazza JP, Stone HH, Meintjes G, Lawn SD, et al. 2013. The phenotype of the CryptococcusspecificCD4 + memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis. J. Infect. Dis. 207:1817-28
125. Jarvis JN, Meintjes G, Bicanic T, Buffa V, Hogan L, et al. 2015. Cerebrospinal fluid cytokine profiles predict risk of early mortality and immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis. PLOS Pathog. 11:e1004754
126. Siddiqui AA, Brouwer AE, Wuthiekanun V, Jaffar S, Shattock R, et al. 2005. IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J. Immunol. 174:1746-50
127. Jarvis JN, Meintjes G, Rebe K, Williams GN, Bicanic T, et al. 2012. Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS 26:1105-13
128. Antonelli LR,Mahnke Y, Hodge JN, Porter BO, Barber DL, et al. 2010. Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood 116:3818-27
129. Barber DL, Mayer-Barber KD, Antonelli LR, Wilson MS, White S, et al. 2010. Th1-driven immune reconstitution disease in Mycobacterium avium-infected mice. Blood 116:3485-93
130. Eschke M, Piehler D, Schulze B, Richter T, Grahnert A, et al. 2015. A novel experimental model of Cryptococcus neoformans-related immune reconstitution inflammatory syndrome (IRIS) provides insights into pathogenesis. Eur. J. Immunol. 45:3339-50
131. Fukuda T, Boeckh M, Carter RA, Sandmaier BM, Maris MB, et al. 2003. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 102:827-33
132. Bodey GP, Buckley M, Sathe YS, Freireich EJ. 1966. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann. Intern. Med. 64:328-40
133. Fan D, Coughlin LA, Neubauer MM, Kim J, Kim MS, et al. 2015. Activation of HIF-1αand LL-37 by commensal bacteria inhibits Candida albicans colonization. Nat. Med. 21:808-14
134. Koh AY, Kohler JR, Coggshall KT, Van Rooijen N, Pier GB. 2008. Mucosal damage and neutropenia are required for Candida albicans dissemination. PLOS Pathog. 4:e35
135. Palchaudhuri R, Saez B,Hoggatt J, Schajnovitz A, SykesDB, et al. 2016. Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. Nat. Biotechnol. 34:738-45
136. Price TH, Boeckh M, Harrison RW, McCullough J, Ness PM, et al. 2015. Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. Blood 126:2153-61
137. Baistrocchi SR, Lee MJ, Lehoux M, Ralph B, Snarr BD, et al. 2017. Posaconazole-loaded leukocytes as a novel treatment strategy targeting invasive pulmonary aspergillosis. J. Infect. Dis. 215:1734-41
138. Wan L, Zhang Y, Lai Y, Jiang M, Song Y, et al. 2015. Effect of granulocyte-macrophage colonystimulating factor on prevention and treatment of invasive fungal disease in recipients of allogeneic stem-cell transplantation: a prospective multicenter randomized phase IV trial. J. Clin. Oncol. 33:3999-4006
139. Kandalla PK, Sarrazin S, MolawiK, Berruyer C, RedelbergerD, et al. 2016. M-CSF improves protection against bacterial and fungal infections after hematopoietic stem/progenitor cell transplantation. J. Exp. Med. 213:2269-79
140. Lionakis MS, Kontoyiannis DP. 2003. Glucocorticoids and invasive fungal infections. Lancet 362:1828-38
141. van de Veerdonk FL, Kolwijck E, Lestrade PPA, Hodiamont CJ, Rijnders BJA, et al.; Dutch Mycoses Study Group. 2017. Influenza-associated aspergillosis in critically ill patients. Am. J. Respir. Crit. Care Med. 196:524-27
142. Bochud PY, Chien JW, Marr KA, Leisenring WM, Upton A, et al. 2008. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N. Engl. J. Med. 359:1766-77
143. Fisher CE, Hohl TM, Fan W, Storer BE, Levine DM, et al. 2017. Validation of single nucleotide polymorphisms in invasive aspergillosis following hematopoietic cell transplantation. Blood 129:2693-701
144. Cunha C, Aversa F, Lacerda JF, Busca A,Kurzai O, et al. 2014. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N. Engl. J. Med. 370:421-32
145. Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, et al. 2010. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin. Infect. Dis. 50:1101-11
146. Greenblatt MB, Aliprantis A, Hu B, Glimcher LH. 2010. Calcineurin regulates innate antifungal immunity in neutrophils. J. Exp. Med. 207:923-31
147. SinghN, Alexander BD, LortholaryO,Dromer F,GuptaKL, et al.;Cryptococcal Collab.Transpl. Study Group. 2007. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J. Infect. Dis. 195:756-64
148. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. 2008. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin. Proc. 83:181-94
149. Allendoerfer R, Deepe GS Jr. 2000. Regulation of infection with Histoplasma capsulatum by TNFR1 and-2. J. Immunol. 165:2657-64
150. Furst DE, Wallis R, Broder M, Beenhouwer DO. 2006. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin. Arthritis Rheum. 36:159-67
151. Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, et al. 2015. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N. Engl. J. Med. 373:1318-28
152. Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, et al. 2015. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N. Engl. J. Med. 373:1329-39
153. Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, et al. 2017. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N. Engl. J. Med. 376:1551-60
154. Kyriakidis I, Tragiannidis A, Z undorf I, Groll AH. 2017. Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors. Mycoses 60:493-507
155. Romani L, Mencacci A, Cenci E, Spaccapelo R, Toniatti C, et al. 1996. Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J. Exp. Med. 183:1345-55
156. Osterborg A, Mellstedt H, Keating M. 2002. Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia. Med. Oncol. 19(Suppl.):S21-26
157. Elsegeiny W, Eddens T, Chen K, Kolls JK. 2015. Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia. Infect. Immun. 83:2043-52
158. Martin-Garrido I, Carmona EM, Specks U, Limper AH. 2013. Pneumocystis pneumonia in patients treated with rituximab. Chest 144:258-65
159. Moodley D, Yoshida H, Mostafavi S, Asinovski N, Ortiz-Lopez A, et al. 2016. Network pharmacology of JAK inhibitors. PNAS 113:9852-57
160. Lionakis MS, Dunleavy K, Roschewski M,Widemann BC, Butman JA, et al. 2017. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell 31:833-43.e5
161. Cheah CY, Fowler NH. 2016. Idelalisib in the management of lymphoma. Blood 128:331-36
162. Valenzuela RM, Pula JH, Garwacki D, Cotter J, Kattah JC. 2014. Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab. J. Neurol. Sci. 340:109-11
163. Williams J, Lim R, Tambyah P. 2007. Invasive aspergillosis associated with bevacizumab, a vascular endothelial growth factor inhibitor. Int. J. Infect. Dis. 11:549-50
164. Sillaber C, HerrmannH, Bennett K, RixU, BaumgartnerC, et al. 2009. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur. J. Clin. Investig. 39:1098-109
165. Chang KC, Burnham CA, Compton SM, Rasche DP, Mazuski RJ, et al. 2013. Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit. Care 17:R85
166. Lazar-Molnar E, Gacser A, Freeman GJ, Almo SC, Nathenson SG, Nosanchuk JD. 2008. The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus Histoplasma capsulatum. PNAS 105:2658-63
167. Grimaldi D, Pradier O, Hotchkiss RS, Vincent JL. 2017. Nivolumab plus interferon-gamma in the treatment of intractable mucormycosis. Lancet Infect. Dis. 17:18
168. Levitz SM, Golenbock DT. 2012. Beyond empiricism: informing vaccine development through innate immunity research. Cell 148:1284-92
169. Armstrong-James D, Brown GD, Netea MG, Zelante T, Gresnigt MS, et al. 2017. Immunotherapeutic approaches to treatment of fungal diseases. Lancet Infect. Dis. 17:e393-402
170. Stevens DA, Clemons KV, LiuM. 2011. Developing a vaccine against aspergillosis. Med. Mycol. 49(Suppl. 1):S170-76
171. Wuthrich M, Brandhorst TT, Sullivan TD, Filutowicz H, Sterkel A, et al. 2015. Calnexin induces expansion of antigen-specific CD4+ T cells that confer immunity to fungal ascomycetes via conserved epitopes. Cell Host Microbe 17:452-65
172. Yeaman MR, Filler SG, Schmidt CS, Ibrahim AS, Edwards JE, Hennessey JP Jr. 2014. Applying convergent immunity to innovative vaccines targeting Staphylococcus aureus. Front. Immunol. 5:463
173. Nanjappa SG, Heninger E, Wuthrich M, Gasper DJ, Klein BS. 2012. Tc17 cells mediate vaccine immunity against lethal fungal pneumonia in immune deficient hosts lacking CD4+ T cells. PLOS Pathog. 8:e1002771
174. Wuthrich M, Filutowicz HI,Warner T, DeepeGS Jr., Klein BS. 2003. Vaccine immunity to pathogenic fungi overcomes the requirement for CD4 help in exogenous antigen presentation to CD8+ T cells: implications for vaccine development in immune-deficient hosts. J. Exp. Med. 197:1405-16
175. Narra HP, Shubitz LF, Mandel MA, Trinh HT, Griffin K, et al. 2016. A Coccidioides posadasii CPS1 deletion mutant is avirulent and protects mice from lethal infection. Infect. Immun. 84:3007-16
176. Upadhya R, Lam WC, Maybruck B, Specht CA, Levitz SM, Lodge JK. 2016. Induction of protective immunity to cryptococcal infection in mice by a heat-killed, chitosan-deficient strain of Cryptococcus neoformans. mBio 7:e00547-16
177. Pappagianis D, Val. Fever Study Group. 1993. Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. Am. Rev. Respir. Dis. 148:656-60
178. Nanjappa SG, Klein BS. 2014. Vaccine immunity against fungal infections. Curr. Opin. Immunol. 28:27-33
179. Santos E, Levitz SM. 2014. Fungal vaccines and immunotherapeutics. Cold Spring Harb. Perspect. Med. 4:a019711
180. Levitz SM,Huang H, Ostroff GR, Specht CA. 2015. Exploiting fungal cell wall components in vaccines. Semin. Immunopathol. 37:199-207
181. HuangH, Ostroff GR, Lee CK, Specht CA, Levitz SM. 2010. Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded β-glucan particles. mBio 1:e00164-10
182. Huang H, Ostroff GR, Lee CK, Specht CA, Levitz SM. 2013. Characterization and optimization of the glucan particle-based vaccine platform. Clin. Vaccine Immunol. 20:1585-91
183. Specht CA, Lee CK, Huang H, Tipper DJ, Shen ZT, et al. 2015. Protection against experimental cryptococcosis following vaccination with glucan particles containing Cryptococcus alkaline extracts. mBio 6:e01905-15
184. KingTH, Guo Z,HermreckM, BellgrauD,Rodell TC. 2016. Construction and immunogenicity testing of whole recombinant yeast-based T-cell vaccines. In VaccineDesign: Methods and Protocols, Vol. 2: Vaccines for Veterinary Diseases, ed. S Thomas, pp. 529-45. New York: Springer
185. Levitz SM, Specht CA. 2006. The molecular basis for the immunogenicity of Cryptococcus neoformans mannoproteins. FEMS Yeast Res. 6:513-24
186. Sancho D, Reis e Sousa C. 2012. Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu. Rev. Immunol. 30:491-529
187. Hardison SE, Brown GD. 2012. C-type lectin receptors orchestrate antifungal immunity. Nat. Immunol. 13:817-22
188. Specht CA,Nong S,Dan JM,Lee CK, Levitz SM. 2007. Contribution of glycosylation toTcell responses stimulated by recombinant Cryptococcus neoformans mannoprotein. J. Infect. Dis. 196:796-800
189. Lam JS, Mansour MK, Specht CA, Levitz SM. 2005. A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity. J. Immunol. 175:7496-503
190. Irache JM, Salman HH, Gamazo C, Espuelas S. 2008. Mannose-targeted systems for the delivery of therapeutics. Expert Opin. Drug Deliv. 5:703-24
191. He L-Z, Weidlick J, Sisson C,Marsh HC, Keler T. 2015. Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccine. Cell Mol. Immunol. 12:719-28
192. Dan JM, Wang JP, Lee CK, Levitz SM. 2008. Cooperative stimulation of dendritic cells by Cryptococcus neoformans mannoproteins and CpG oligodeoxynucleotides. PLOS ONE 3:e2046
193. Smith A, Perelman M, Hinchcliffe M. 2014. Chitosan. Hum. Vaccines Immunother. 10:797-807
194. Bueter CL, Lee CK, Wang JP, Ostroff GR, Specht CA, Levitz SM. 2014. Spectrum and mechanisms of inflammasome activation by chitosan. J. Immunol. 192:5943-51
195. Larsen RA, Pappas PG, Perfect J, Aberg JA, Casadevall A, et al. 2005. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob. Agents Chemother. 49:952-58
196. Cywes-Bentley C, Skurnik D, Zaidi T, Roux D, Deoliveira RB, et al. 2013. Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens. PNAS 110:E2209-18
197. Bozza S, Perruccio K, Montagnoli C, Gaziano R, Bellocchio S, et al. 2003. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 102:3807-14
198. Perruccio K, Tosti A, Burchielli E, Topini F, Ruggeri L, et al. 2005. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 106:4397-406
199. Stuehler C, Nowakowska J, Bernardini C, Topp MS, Battegay M, et al. 2015. Multispecific Aspergillus T cells selected by CD137 or CD154 induce protective immune responses against the most relevant mold infections. J. Infect. Dis. 211:1251-61
200. Kumaresan PR, Manuri PR, Albert ND, Maiti S, Singh H, et al. 2014. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. PNAS 111:10660-65